These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 10870061)
1. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Yamada SD; Burger RA; Brewster WR; Anton D; Kohler MF; Monk BJ Cancer; 2000 Jun; 88(12):2782-6. PubMed ID: 10870061 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900 [TBL] [Abstract][Full Text] [Related]
3. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359 [TBL] [Abstract][Full Text] [Related]
4. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850 [TBL] [Abstract][Full Text] [Related]
5. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Temkin SM; Hellmann M; Lee YC; Abulafia O Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256 [TBL] [Abstract][Full Text] [Related]
6. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780 [TBL] [Abstract][Full Text] [Related]
9. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. Zhu J; Wen H; Bi R; Wu X J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439 [TBL] [Abstract][Full Text] [Related]
11. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gerszten K; Faul C; Kounelis S; Huang Q; Kelley J; Jones MW Gynecol Oncol; 1998 Jan; 68(1):8-13. PubMed ID: 9454652 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy and prognosis in uterine carcinosarcoma. Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491 [TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838 [TBL] [Abstract][Full Text] [Related]
14. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654 [TBL] [Abstract][Full Text] [Related]
15. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy? Velker V; D'Souza D; Prefontaine M; McGee J; Leung E Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823 [TBL] [Abstract][Full Text] [Related]
16. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418 [TBL] [Abstract][Full Text] [Related]